Moleculin Biotech, Inc. (MBRX) announced new preclinical data for its lead drug candidate, Annamycin (naxtarubicin), showing its antitumor activity in pancreatic cancer is partially driven by an immune response. The findings suggest Annamycin may make immunologically "cold" tumors susceptible to immune attack, a significant development for a typically treatment-resistant cancer. The data is being presented at the AACR Conference on Pancreatic Cancer.
Key Details
- Key Finding: Preclinical models show Annamycin's activity is partly mediated by CD8+ T cells, the immune system's primary tumor-killing cells.
- Presentation: The data is being presented at the AACR Conference on Pancreatic Cancer in San Diego, CA, from September 25-28, 2026.
- Strategic Context: While promising, these are preclinical results. The company's lead clinical program for Annamycin remains its pivotal trial for relapsed or refractory acute myeloid leukemia (AML).